Brief: Hls Therapeutics Announces Fiscal 2023 Financial Results
14/03/2024 11:59
March 14 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES FISCAL 2023 FINANCIAL RESULTS
* HLS IS TARGETING 2024 CONSOLIDATED REVENUE OF $63.5-66.5
MILLION, OR 1-5% GROWTH
* LOOKING AHEAD TO 2025 AND BEYOND, WE EXPECT CONSOLIDATED
REVENUE
AND ADJUSTED EBITDA GROWTH TO IMPROVE CONSIDERABLY
* AMENDED TERMS OF ITS CREDIT AGREEMENT TO MODIFY CERTAIN
COVENANT
RATIOS
* UNDER AMENDED AGREEMENT, COMPANY'S REVOLVING FACILITY HAS
BEEN
REDUCED TO $25 MILLION FROM $30 MILLION
Source text for Eikon: ID:nCNWmvrMfa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group